28th Mar 2019 07:00
March 28, 2019
Verseon Corporation
("Verseon" or the "Company")
Further Update to Admission of Subscription Shares
FREMONT, Calif.-Verseon, a clinical-stage pharmaceutical company developing disruptive life-science technologies to advance global health, today announces that further to the announcement on March 22, 2019, the Directors now expect that Admission of the Subscription Shares, under a separate ISIN for Regulation S restricted stock, will take place on or around Tuesday, April 2, 2019.
About Verseon
Verseon Corporation (AIM:VERS) is developing disruptive life-science technology to advance global health. The clinical-stage company is using its proprietary, computational drug discovery platform to discover new drug candidates that are unlikely to be found using conventional methods. Pairing its computational engines with a comprehensive in-house chemistry and biology workflow, the company has built a growing pipeline of drug programs. Verseon currently has four active drug programs in the areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology.
Find Verseon on Twitter and LinkedIn.
- Ends -
For further information, please contact:
Verseon Corporation | www.verseon.com |
Sebastian Wykeham / Tina Schlafly | +1 (510) 225 9000 |
Arden Partners (NOMAD and Joint Broker) | |
Ruari McGirr / Ciaran Walsh / Alex Penney | +44 (0) 20 7614 5900 |
Cantor Fitzgerald Europe (Joint Broker) | |
Phil Davies | +44 (0) 20 7894 7000 |
For financial and business media enquiries, please contact
Buchanan Communications Ltd (PR Advisers) | |
Henry Harrison-Topham / Jamie Hooper | +44 (0) 20 7466 5000 |
For trade and pharma media enquiries, please contact
Vane Percy & Roberts | |
Simon Vane Percy | +44 (0) 1737 821 890 |
Related Shares:
VERS.L